{"id":350455,"date":"2025-08-25T19:27:20","date_gmt":"2025-08-25T19:27:20","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-arvinas\/"},"modified":"2025-08-25T19:27:20","modified_gmt":"2025-08-25T19:27:20","slug":"how-to-buy-arvinas","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/","title":{"rendered":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-350455","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Arvinas, Inc. (ARVN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve FDA kataliz\u00f6rleriyle gelecek vadeden bu biyotek hisse senedinde bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 verin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Arvinas, Inc. (ARVN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve FDA kataliz\u00f6rleriyle gelecek vadeden bu biyotek hisse senedinde bilin\u00e7li yat\u0131r\u0131m kararlar\u0131 verin."},"intro":"Kanser tedavisinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arvinas \u015fu anda biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Bu \u015firket, hastal\u0131klar\u0131 tedavi etme \u015feklimizi devrim niteli\u011finde de\u011fi\u015ftirebilecek protein bozunumu teknolojisinde \u00f6nc\u00fcl\u00fck ediyor. ARVN hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi\u2014mevcut performanstan yat\u0131r\u0131m\u0131n\u0131z\u0131 \u015fekillendirebilecek kritik FDA kararlar\u0131na kadar\u2014ayr\u0131nt\u0131l\u0131 olarak a\u00e7\u0131klayaca\u011f\u0131z.","intro_source":{"label":"Intro","type":"text","formatted_value":"Kanser tedavisinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arvinas \u015fu anda biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Bu \u015firket, hastal\u0131klar\u0131 tedavi etme \u015feklimizi devrim niteli\u011finde de\u011fi\u015ftirebilecek protein bozunumu teknolojisinde \u00f6nc\u00fcl\u00fck ediyor. ARVN hisselerine yat\u0131r\u0131m yaparken bilmeniz gereken her \u015feyi\u2014mevcut performanstan yat\u0131r\u0131m\u0131n\u0131z\u0131 \u015fekillendirebilecek kritik FDA kararlar\u0131na kadar\u2014ayr\u0131nt\u0131l\u0131 olarak a\u00e7\u0131klayaca\u011f\u0131z."},"body_html":"<h2>\ud83d\udcc8 Arvinas Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Arvinas, Inc. (ARVN) NASDAQ'ta <strong>7,39 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>29 Ekim 2025<\/strong> kesinlikle kritik\u2014Arvinas'\u0131n 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlarda dramatik hareketlere neden olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 ARVN Hissesini Nas\u0131l Hareket Ettirir<\/h3> <p>6 A\u011fustos 2025'teki son kazan\u00e7 raporu \u00f6nemli volatilite yaratt\u0131. \u015eirket, Pfizer ile i\u015f birli\u011fi gelirlerindeki azalma ve Vepdegestrant i\u00e7in kar\u0131\u015f\u0131k klinik sonu\u00e7lar nedeniyle gelirlerinde %71 d\u00fc\u015f\u00fc\u015fle 22,4 milyon $ bildirdi. Bu, hisse senedinin sonraki hafta yakla\u015f\u0131k %15 d\u00fc\u015fmesine yol a\u00e7t\u0131.<\/p> <p>Son d\u00f6neme bak\u0131ld\u0131\u011f\u0131nda:<\/p> <ul> <li><strong>\u015eubat 2025<\/strong>: 4. \u00e7eyrek kazan\u00e7lar\u0131 hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan deneme g\u00fcncellemeleri nedeniyle %12 d\u00fc\u015f\u00fc\u015fe neden oldu<\/li> <li><strong>Kas\u0131m 2024<\/strong>: Genentech ile ortakl\u0131k haberi %22'lik bir y\u00fckseli\u015f ba\u015flatt\u0131<\/li> <li><strong>A\u011fustos 2024<\/strong>: 2. \u00e7eyrek sonu\u00e7lar\u0131 ilerleme g\u00f6sterdi ancak gelir tahminlerini kar\u015f\u0131layamad\u0131, %8 d\u00fc\u015f\u00fc\u015fe yol a\u00e7t\u0131<\/li> <li><strong>May\u0131s 2024<\/strong>: Pozitif Faz 2 verileri iki hafta i\u00e7inde %30 art\u0131\u015f yaratt\u0131<\/li> <\/ul> <p>Desen a\u00e7\u0131k: ARVN, klinik deneme sonu\u00e7lar\u0131na ve ortakl\u0131k duyurular\u0131na g\u00fc\u00e7l\u00fc tepki veriyor. Yakla\u015fan Ekim kazan\u00e7lar\u0131, son gelir zorluklar\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6zellikle volatil olabilir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>Arvinas hisseleri son alt\u0131 ayda adeta bir h\u0131z treni ya\u015fad\u0131:<\/p> <p><strong>\u015eubat 2025<\/strong>: 9,80 $ (4. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131 sonras\u0131)<br\/> <strong>Mart 2025<\/strong>: 11,20 $ (ortakl\u0131k iyimserli\u011fiyle toparlanma)<br\/> <strong>Nisan 2025<\/strong>: 8,90 $ (sekt\u00f6r genelinde biyotek sat\u0131\u015flar\u0131ndan kaynaklanan volatilite)<br\/> <strong>May\u0131s 2025<\/strong>: 10,50 $ (pozitif analist y\u00fckseltmeleri)<br\/> <strong>Haziran 2025<\/strong>: 7,20 $ (gelir endi\u015feleriyle keskin d\u00fc\u015f\u00fc\u015f)<br\/> <strong>Temmuz 2025<\/strong>: 6,80 $ (52 haftal\u0131k dip seviyeye dokundu)<br\/> <strong>A\u011fustos 2025<\/strong>: 7,39 $ (mevcut stabilizasyon)<\/p> <p>Bu, alt\u0131 ayl\u0131k d\u00f6nemde <strong>%24,6 d\u00fc\u015f\u00fc\u015f<\/strong> anlam\u0131na geliyor ve ba\u015fl\u0131ca nedenleri:<\/p> <ul> <li>Klinik deneme belirsizlikleri<\/li> <li>Pfizer i\u015f birliklerinden kaynaklanan gelir a\u00e7\u0131klar\u0131<\/li> <li>Daha geni\u015f biyotek sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k<\/li> <\/ul> <p>Ancak, hisse senedi 7 $ destek seviyesinde diren\u00e7 g\u00f6stererek potansiyel stabilizasyona i\u015faret ediyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik geli\u015fim takvimlerine dayanarak:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 14-18 $ aral\u0131\u011f\u0131 (stabilizasyon ve \u0131l\u0131ml\u0131 toparlanma varsay\u0131m\u0131yla) \u2192 <strong>uzun vadeli ALIM<\/strong><\/li> <li><strong>2026 Hedef<\/strong>: 20-25 $ (Vepdegestrant i\u00e7in FDA karar\u0131 Haziran 2026'da bekleniyor)<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 35-45 $ (potansiyel ticarile\u015fme ve geni\u015fleyen ortakl\u0131klar)<\/li> <li><strong>2030 Vizyonu<\/strong>: 60-80+ $ (protein bozunumu platformu birden fazla endikasyonda ba\u015far\u0131l\u0131 olursa)<\/li> <\/ul> <p>Ortalama analist fiyat hedefi, <a href=\"https:\/\/stockanalysis.com\/stocks\/arvn\/forecast\/\">StockAnalysis.com<\/a> verilerine g\u00f6re <strong>20,21 $<\/strong> seviyesinde olup, mevcut seviyelerden %176 y\u00fckseli\u015f potansiyeli sunmaktad\u0131r.<\/p> <h3>Neden Uzun Vadede Bo\u011fa G\u00f6r\u00fc\u015f\u00fc Var?<\/h3> <ol> <li><strong>FDA Kataliz\u00f6r\u00fc<\/strong>: Vepdegestrant i\u00e7in 5 Haziran 2026 PDUFA tarihi<\/li> <li><strong>Platform Potansiyeli<\/strong>: PROTAC teknolojisi \"ila\u00e7 verilemeyen\" hedefleri ele alabilir<\/li> <li><strong>G\u00fc\u00e7l\u00fc Ortakl\u0131klar<\/strong>: Pfizer i\u015f birli\u011fi geli\u015ftirme riskini azalt\u0131yor<\/li> <li><strong>Nakit Durumu<\/strong>: En son raporlara g\u00f6re 2028 sonuna kadar yeterli fon<\/li> <\/ol> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90'\u0131 ge\u00e7 evre denemelerde ba\u015far\u0131s\u0131z olur<\/li> <li><strong>Reg\u00fclasyon Gecikmeleri<\/strong>: FDA kararlar\u0131 ertelenebilir veya ek veri talep edebilir<\/li> <li><strong>Gelir Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Ticarile\u015fmeye kadar ortakl\u0131k \u00f6demelerine y\u00fcksek ba\u011f\u0131ml\u0131l\u0131k<\/li> <li><strong>Y\u00fcksek Volatilite<\/strong>: 1,58 beta de\u011feri piyasa volatilitesinden %58 daha fazla<\/li> <li><strong>\u0130kili Olaylar<\/strong>: Hisse fiyat\u0131 birka\u00e7 kritik kataliz\u00f6re \u00e7ok ba\u011fl\u0131<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>FDA Kabul\u00fc<\/strong>: Vepdegestrant NDA Haziran 2026 karar tarihiyle kabul edildi<\/li> <li><strong>Faz 3 Ba\u015far\u0131s\u0131<\/strong>: Denemelerde hastal\u0131k ilerlemesinde %43 risk azalmas\u0131 g\u00f6sterildi<\/li> <li><strong>Kurumsal Destek<\/strong>: XTX Topco, 2025 1. \u00e7eyrekte pay\u0131n\u0131 %194 art\u0131rd\u0131<\/li> <li><strong>Analist G\u00fcveni<\/strong>: 12 al\u0131m, 9 tutma, s\u0131f\u0131r sat\u0131m \u00f6nerisi<\/li> <li><strong>Teknoloji Do\u011frulamas\u0131<\/strong>: \u0130lk PROTAC ilac\u0131 FDA incelemesine yakla\u015f\u0131yor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyotek hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 29 Ekim kazan\u00e7lar\u0131 gibi kritik tarihlerde takipte olun<\/li> <li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/strong>: \u0130\u015fleme girmeden \u00f6nce zarar durdurma seviyelerinizi bilin<\/li> <\/ol> <p>Mizahi bir bak\u0131\u015f: \"ARVN ticareti yapmak, bir t\u0131bbi drama izlemek gibidir\u2014bolca gerilim, ara s\u0131ra at\u0131l\u0131mlar ve sezon finali (FDA karar\u0131) i\u00e7in g\u00fc\u00e7l\u00fc sinirler gerektirir!\"<\/p> <h2>\u2705 Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve kesirli hisse sunan bir platform oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"ARVN\" aramas\u0131 yap\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonunuzu izleyin<\/td><td>Haberler ve fiyat hareketleri i\u00e7in uyar\u0131lar kurun<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Biyotek yat\u0131r\u0131m\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong> \u2014 k\u00fc\u00e7\u00fck miktarlarla strateji test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> \u2014 herhangi bir resmi kimlikle genellikle 1 dakikadan k\u0131sa s\u00fcrede<\/li> <li><strong>Kesirli hisse imkan\u0131<\/strong> \u2014 pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> \u2014 kripto, e-c\u00fczdanlar ve banka transferleri dahil<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan ARVN gibi biyotek hisselerini ke\u015ffetmek isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Arvinas: Protein Bozunumu \u00d6nc\u00fcs\u00fc<\/h2> <p>Arvinas, hedefe y\u00f6nelik protein bozunumu teknolojisinde \u00f6n saflarda yer al\u0131yor. \u015eirketin PROTAC platformu, geleneksel inhibit\u00f6r yakla\u015f\u0131mlar\u0131 yerine v\u00fccudun do\u011fal protein at\u0131m sistemini kullanarak hastal\u0131klar\u0131n tedavisinde potansiyel bir paradigma de\u011fi\u015fikli\u011fi temsil ediyor.<\/p> <ul> <li><strong>Mevcut Odak<\/strong>: Meme kanseri i\u00e7in Vepdegestrant'\u0131n ilerletilmesi, FDA karar\u0131 Haziran 2026'da bekleniyor<\/li> <li><strong>Pipeline G\u00fcc\u00fc<\/strong>: Prostat kanseri ve di\u011fer endikasyonlar i\u00e7in Faz 3 denemelerinde birden fazla aday<\/li> <li><strong>Ortakl\u0131k G\u00fcc\u00fc<\/strong>: Pfizer, Genentech ve Bayer ile i\u015f birlikleri finansal istikrar sa\u011fl\u0131yor<\/li> <\/ul> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Arvinas bilim insanlar\u0131, protein bozucular\u0131n\u0131n \"i\u015fgal odakl\u0131\" yerine \"olay odakl\u0131\" tasarlanabilece\u011fini ke\u015ffettiler; yani sadece gerekti\u011finde \u00e7al\u0131\u015f\u0131yor ve sonra do\u011fal olarak ayr\u0131l\u0131yorlar\u2014bu, yan etkileri \u00f6nemli \u00f6l\u00e7\u00fcde azaltabilecek bir at\u0131l\u0131m.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Arvinas Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Arvinas, Inc. (ARVN) NASDAQ&#8217;ta <strong>7,39 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>29 Ekim 2025<\/strong> kesinlikle kritik\u2014Arvinas&#8217;\u0131n 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 tarih. Tarihsel olarak, bu raporlar fiyatlarda dramatik hareketlere neden olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 ARVN Hissesini Nas\u0131l Hareket Ettirir<\/h3>\n<p>6 A\u011fustos 2025&#8217;teki son kazan\u00e7 raporu \u00f6nemli volatilite yaratt\u0131. \u015eirket, Pfizer ile i\u015f birli\u011fi gelirlerindeki azalma ve Vepdegestrant i\u00e7in kar\u0131\u015f\u0131k klinik sonu\u00e7lar nedeniyle gelirlerinde %71 d\u00fc\u015f\u00fc\u015fle 22,4 milyon $ bildirdi. Bu, hisse senedinin sonraki hafta yakla\u015f\u0131k %15 d\u00fc\u015fmesine yol a\u00e7t\u0131.<\/p>\n<p>Son d\u00f6neme bak\u0131ld\u0131\u011f\u0131nda:<\/p>\n<ul>\n<li><strong>\u015eubat 2025<\/strong>: 4. \u00e7eyrek kazan\u00e7lar\u0131 hayal k\u0131r\u0131kl\u0131\u011f\u0131 yaratan deneme g\u00fcncellemeleri nedeniyle %12 d\u00fc\u015f\u00fc\u015fe neden oldu<\/li>\n<li><strong>Kas\u0131m 2024<\/strong>: Genentech ile ortakl\u0131k haberi %22&#8217;lik bir y\u00fckseli\u015f ba\u015flatt\u0131<\/li>\n<li><strong>A\u011fustos 2024<\/strong>: 2. \u00e7eyrek sonu\u00e7lar\u0131 ilerleme g\u00f6sterdi ancak gelir tahminlerini kar\u015f\u0131layamad\u0131, %8 d\u00fc\u015f\u00fc\u015fe yol a\u00e7t\u0131<\/li>\n<li><strong>May\u0131s 2024<\/strong>: Pozitif Faz 2 verileri iki hafta i\u00e7inde %30 art\u0131\u015f yaratt\u0131<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: ARVN, klinik deneme sonu\u00e7lar\u0131na ve ortakl\u0131k duyurular\u0131na g\u00fc\u00e7l\u00fc tepki veriyor. Yakla\u015fan Ekim kazan\u00e7lar\u0131, son gelir zorluklar\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6zellikle volatil olabilir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>Arvinas hisseleri son alt\u0131 ayda adeta bir h\u0131z treni ya\u015fad\u0131:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: 9,80 $ (4. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131 sonras\u0131)<br \/> <strong>Mart 2025<\/strong>: 11,20 $ (ortakl\u0131k iyimserli\u011fiyle toparlanma)<br \/> <strong>Nisan 2025<\/strong>: 8,90 $ (sekt\u00f6r genelinde biyotek sat\u0131\u015flar\u0131ndan kaynaklanan volatilite)<br \/> <strong>May\u0131s 2025<\/strong>: 10,50 $ (pozitif analist y\u00fckseltmeleri)<br \/> <strong>Haziran 2025<\/strong>: 7,20 $ (gelir endi\u015feleriyle keskin d\u00fc\u015f\u00fc\u015f)<br \/> <strong>Temmuz 2025<\/strong>: 6,80 $ (52 haftal\u0131k dip seviyeye dokundu)<br \/> <strong>A\u011fustos 2025<\/strong>: 7,39 $ (mevcut stabilizasyon)<\/p>\n<p>Bu, alt\u0131 ayl\u0131k d\u00f6nemde <strong>%24,6 d\u00fc\u015f\u00fc\u015f<\/strong> anlam\u0131na geliyor ve ba\u015fl\u0131ca nedenleri:<\/p>\n<ul>\n<li>Klinik deneme belirsizlikleri<\/li>\n<li>Pfizer i\u015f birliklerinden kaynaklanan gelir a\u00e7\u0131klar\u0131<\/li>\n<li>Daha geni\u015f biyotek sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k<\/li>\n<\/ul>\n<p>Ancak, hisse senedi 7 $ destek seviyesinde diren\u00e7 g\u00f6stererek potansiyel stabilizasyona i\u015faret ediyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik geli\u015fim takvimlerine dayanarak:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 14-18 $ aral\u0131\u011f\u0131 (stabilizasyon ve \u0131l\u0131ml\u0131 toparlanma varsay\u0131m\u0131yla) \u2192 <strong>uzun vadeli ALIM<\/strong><\/li>\n<li><strong>2026 Hedef<\/strong>: 20-25 $ (Vepdegestrant i\u00e7in FDA karar\u0131 Haziran 2026&#8217;da bekleniyor)<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 35-45 $ (potansiyel ticarile\u015fme ve geni\u015fleyen ortakl\u0131klar)<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 60-80+ $ (protein bozunumu platformu birden fazla endikasyonda ba\u015far\u0131l\u0131 olursa)<\/li>\n<\/ul>\n<p>Ortalama analist fiyat hedefi, <a href=\"https:\/\/stockanalysis.com\/stocks\/arvn\/forecast\/\">StockAnalysis.com<\/a> verilerine g\u00f6re <strong>20,21 $<\/strong> seviyesinde olup, mevcut seviyelerden %176 y\u00fckseli\u015f potansiyeli sunmaktad\u0131r.<\/p>\n<h3>Neden Uzun Vadede Bo\u011fa G\u00f6r\u00fc\u015f\u00fc Var?<\/h3>\n<ol>\n<li><strong>FDA Kataliz\u00f6r\u00fc<\/strong>: Vepdegestrant i\u00e7in 5 Haziran 2026 PDUFA tarihi<\/li>\n<li><strong>Platform Potansiyeli<\/strong>: PROTAC teknolojisi &#8220;ila\u00e7 verilemeyen&#8221; hedefleri ele alabilir<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Ortakl\u0131klar<\/strong>: Pfizer i\u015f birli\u011fi geli\u015ftirme riskini azalt\u0131yor<\/li>\n<li><strong>Nakit Durumu<\/strong>: En son raporlara g\u00f6re 2028 sonuna kadar yeterli fon<\/li>\n<\/ol>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90&#8217;\u0131 ge\u00e7 evre denemelerde ba\u015far\u0131s\u0131z olur<\/li>\n<li><strong>Reg\u00fclasyon Gecikmeleri<\/strong>: FDA kararlar\u0131 ertelenebilir veya ek veri talep edebilir<\/li>\n<li><strong>Gelir Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: Ticarile\u015fmeye kadar ortakl\u0131k \u00f6demelerine y\u00fcksek ba\u011f\u0131ml\u0131l\u0131k<\/li>\n<li><strong>Y\u00fcksek Volatilite<\/strong>: 1,58 beta de\u011feri piyasa volatilitesinden %58 daha fazla<\/li>\n<li><strong>\u0130kili Olaylar<\/strong>: Hisse fiyat\u0131 birka\u00e7 kritik kataliz\u00f6re \u00e7ok ba\u011fl\u0131<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>FDA Kabul\u00fc<\/strong>: Vepdegestrant NDA Haziran 2026 karar tarihiyle kabul edildi<\/li>\n<li><strong>Faz 3 Ba\u015far\u0131s\u0131<\/strong>: Denemelerde hastal\u0131k ilerlemesinde %43 risk azalmas\u0131 g\u00f6sterildi<\/li>\n<li><strong>Kurumsal Destek<\/strong>: XTX Topco, 2025 1. \u00e7eyrekte pay\u0131n\u0131 %194 art\u0131rd\u0131<\/li>\n<li><strong>Analist G\u00fcveni<\/strong>: 12 al\u0131m, 9 tutma, s\u0131f\u0131r sat\u0131m \u00f6nerisi<\/li>\n<li><strong>Teknoloji Do\u011frulamas\u0131<\/strong>: \u0130lk PROTAC ilac\u0131 FDA incelemesine yakla\u015f\u0131yor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyotek hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Zamanlama riskini azaltmak i\u00e7in toplu de\u011fil par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: 29 Ekim kazan\u00e7lar\u0131 gibi kritik tarihlerde takipte olun<\/li>\n<li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/strong>: \u0130\u015fleme girmeden \u00f6nce zarar durdurma seviyelerinizi bilin<\/li>\n<\/ol>\n<p>Mizahi bir bak\u0131\u015f: &#8220;ARVN ticareti yapmak, bir t\u0131bbi drama izlemek gibidir\u2014bolca gerilim, ara s\u0131ra at\u0131l\u0131mlar ve sezon finali (FDA karar\u0131) i\u00e7in g\u00fc\u00e7l\u00fc sinirler gerektirir!&#8221;<\/p>\n<h2>\u2705 Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve kesirli hisse sunan bir platform oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;ARVN&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonunuzu izleyin<\/td>\n<td>Haberler ve fiyat hareketleri i\u00e7in uyar\u0131lar kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Biyotek yat\u0131r\u0131m\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong> \u2014 k\u00fc\u00e7\u00fck miktarlarla strateji test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> \u2014 herhangi bir resmi kimlikle genellikle 1 dakikadan k\u0131sa s\u00fcrede<\/li>\n<li><strong>Kesirli hisse imkan\u0131<\/strong> \u2014 pahal\u0131 hisselerin par\u00e7alar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> \u2014 kripto, e-c\u00fczdanlar ve banka transferleri dahil<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan ARVN gibi biyotek hisselerini ke\u015ffetmek isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Arvinas: Protein Bozunumu \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Arvinas, hedefe y\u00f6nelik protein bozunumu teknolojisinde \u00f6n saflarda yer al\u0131yor. \u015eirketin PROTAC platformu, geleneksel inhibit\u00f6r yakla\u015f\u0131mlar\u0131 yerine v\u00fccudun do\u011fal protein at\u0131m sistemini kullanarak hastal\u0131klar\u0131n tedavisinde potansiyel bir paradigma de\u011fi\u015fikli\u011fi temsil ediyor.<\/p>\n<ul>\n<li><strong>Mevcut Odak<\/strong>: Meme kanseri i\u00e7in Vepdegestrant&#8217;\u0131n ilerletilmesi, FDA karar\u0131 Haziran 2026&#8217;da bekleniyor<\/li>\n<li><strong>Pipeline G\u00fcc\u00fc<\/strong>: Prostat kanseri ve di\u011fer endikasyonlar i\u00e7in Faz 3 denemelerinde birden fazla aday<\/li>\n<li><strong>Ortakl\u0131k G\u00fcc\u00fc<\/strong>: Pfizer, Genentech ve Bayer ile i\u015f birlikleri finansal istikrar sa\u011fl\u0131yor<\/li>\n<\/ul>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Arvinas bilim insanlar\u0131, protein bozucular\u0131n\u0131n &#8220;i\u015fgal odakl\u0131&#8221; yerine &#8220;olay odakl\u0131&#8221; tasarlanabilece\u011fini ke\u015ffettiler; yani sadece gerekti\u011finde \u00e7al\u0131\u015f\u0131yor ve sonra do\u011fal olarak ayr\u0131l\u0131yorlar\u2014bu, yan etkileri \u00f6nemli \u00f6l\u00e7\u00fcde azaltabilecek bir at\u0131l\u0131m.<\/p>\n"},"faq":[{"question":"Arvinas, Inc. (ARVN) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"ARVN hisselerini sat\u0131n almak i\u00e7in NASDAQ listesi sunan bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, ARVN sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve pozisyonunuzu d\u00fczenli olarak izleyin."},{"question":"Arvinas hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"Ana fakt\u00f6rler aras\u0131nda klinik deneme sonu\u00e7lar\u0131, FDA kararlar\u0131, ortakl\u0131k duyurular\u0131 ve gelir performans\u0131 yer al\u0131r. Bu fakt\u00f6rler hisse fiyat\u0131nda \u00f6nemli dalgalanmalara neden olabilir."},{"question":"Arvinas'\u0131n FDA onay s\u00fcreci ne zaman tamamlanacak?","answer":"Vepdegestrant i\u00e7in FDA'n\u0131n PDUFA karar\u0131 5 Haziran 2026 tarihinde beklenmektedir."},{"question":"Arvinas hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"Analistlerin ortalama fiyat hedefi 2025 sonunda 14-18 $, 2026'da 20-25 $, 2028'de 35-45 $ ve 2030'da 60-80 $+ aral\u0131\u011f\u0131nda \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar Arvinas hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, kritik tarihlerde fiyat uyar\u0131lar\u0131 kurun ve zarar durdurma seviyelerinizi \u00f6nceden belirleyin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Arvinas, Inc. (ARVN) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"ARVN hisselerini sat\u0131n almak i\u00e7in NASDAQ listesi sunan bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, ARVN sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve pozisyonunuzu d\u00fczenli olarak izleyin."},{"question":"Arvinas hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"Ana fakt\u00f6rler aras\u0131nda klinik deneme sonu\u00e7lar\u0131, FDA kararlar\u0131, ortakl\u0131k duyurular\u0131 ve gelir performans\u0131 yer al\u0131r. Bu fakt\u00f6rler hisse fiyat\u0131nda \u00f6nemli dalgalanmalara neden olabilir."},{"question":"Arvinas'\u0131n FDA onay s\u00fcreci ne zaman tamamlanacak?","answer":"Vepdegestrant i\u00e7in FDA'n\u0131n PDUFA karar\u0131 5 Haziran 2026 tarihinde beklenmektedir."},{"question":"Arvinas hisseleri i\u00e7in uzun vadeli fiyat tahmini nedir?","answer":"Analistlerin ortalama fiyat hedefi 2025 sonunda 14-18 $, 2026'da 20-25 $, 2028'de 35-45 $ ve 2030'da 60-80 $+ aral\u0131\u011f\u0131nda \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar Arvinas hisselerine yat\u0131r\u0131m yaparken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, kritik tarihlerde fiyat uyar\u0131lar\u0131 kurun ve zarar durdurma seviyelerinizi \u00f6nceden belirleyin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T19:27:20+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T19:27:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/\",\"name\":\"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-25T19:27:20+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/","og_locale":"tr_TR","og_type":"article","og_title":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T19:27:20+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T19:27:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/","name":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-25T19:27:20+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arvinas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Arvinas, Inc. (ARVN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arvinas, Inc. (ARVN) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":350457,"slug":"how-to-buy-arvinas","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Arvinas, Inc. (ARVN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-arvinas\/"},"pt_AA":{"locale":"pt_AA","id":350459,"slug":"how-to-buy-arvinas","post_title":"Como comprar a\u00e7\u00f5es da Arvinas, Inc. (ARVN) - Investimento em a\u00e7\u00f5es da Arvinas, Inc. (ARVN)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-arvinas\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/350455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=350455"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/350455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=350455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=350455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=350455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}